Menopausal Syndrome

2020 ◽  
Author(s):  
Keyword(s):  
Menopausal Syndrome

THE TREATMENT OF THE MENOPAUSAL SYNDROME WITH DHEA-SULFATE

1969 ◽  
Vol 61 (1_Suppl) ◽  
pp. S230 ◽  
Author(s):  
Walther Rindt ◽  
G. Heinen ◽  
G. W. Oertel
Keyword(s):  
Menopausal Syndrome

Possibilities of correction of menopausal disorders in women with the use of medicine Menopace

2016 ◽  
pp. 95-100
Author(s):  
G.I. Reznichenko ◽  
◽  
N.Yu. Reznichenko ◽  
V.Yu. Potebnya ◽  
K.I. Kovalenko ◽  
...  
Keyword(s):  
General Condition ◽  
Clinical Symptoms ◽  
Average Score ◽  
Control Group ◽  
Climacteric Syndrome ◽  
Basic Subgroup ◽  
Menopausal Syndrome ◽  
Natural Menopause ◽  
Surgical Menopause ◽  
Observation Period

The objective: to determine the efficacy of medicine «Menopace» in treatment of women with natural and surgical menopause. Patients and methods. 20 women (I group) with a natural menopause were examined (basic subgroup consisted of 10 patients who used Menopace for 3 months; control subgroup consisted of 10 patients). 20 women (II group) with surgical menopause were examined (basic subgroup consisted of 10 patients who received Menopace for 3 months; control subgroup consisted of 10 patients). Results. The average score of neurovegetative and emotional manifestations of climacteric syndrome during the observation period decreased in women with natural and surgical menopause who used Menopace, compared with subgroups of patients who had not used the medicine. Conclusions. 1. The use of the medicine Menopace in women with natural menopause after 3 months showed the disappearance of clinical symptoms of climacteric syndrome in 70% of the cases, and significant improvement in general condition in 30% of cases. 2. During surgical menopause after 1 month of treatment with Menopace manifestations of sweating were observed 4.5 times less often than in control group, tides were observed 7 times less often than in control group. Neurovegetative and psychoemotional symptoms of menopause were absent in 80% of women after 3 months of treatment and in 20% of cases significant improvement was shown. 3. The obtained results give grounds to recommend wide use of Menopace in practical work for the treatment of menopausal syndrome during natural and surgical menopause. Key words: menopause, therapy, Menopace.

Ladder of life of a modern woman: how to maintain health. Opportunities and prospects of phytotherapy (to help a practitioner)

GYNECOLOGY ◽  
2019 ◽  
Vol 21 (2) ◽  
pp. 12-17 ◽  
Author(s):  
Vera N Prilepskaya ◽  
Elena G Nazarenko
Keyword(s):  
Reproductive System ◽  
Premenstrual Syndrome ◽  
Herbal Remedies ◽  
Herbal Therapy ◽  
Menopausal Syndrome ◽  
Safety And Efficacy ◽  
Modern View ◽  
Pathological Conditions

The article provides a modern view on features of different stages of a woman’s life. It presents information on pathogenetic basis and effectiveness of modern phytotherapy with a use of certified agents for a treatment of main pathological conditions associated with different stages of a woman’s life when the hypothalamic-pituitary-ovarian system’s function is formed, actively functions and then undergoes a gradual involution. The features of the use of herbal remedies in pathological conditions of the reproductive system (premenstrual syndrome, hyperprolactinemia, menopausal syndrome, mastalgia, etc.) are described. The article is illustrated with figures and tables for better understanding by clinicians. It emphasis on the features of herbal therapy, its high acceptability, safety and efficacy in the age aspect.

Dynamics of symptoms of genitourinary menopausal syndrome and the frequency of recurrence of lower urinary tract infection in women in periand postmenopausal patients with combined therapy with Trioginal®

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 67-72
Author(s):  
D Yu Pushkar ◽  
M Yu Gvozdev
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Urine Culture ◽  
Objective Assessment ◽  
Control Group ◽  
Urination Disorders ◽  
Menopausal Syndrome ◽  
Tract Infections ◽  
Two Stages ◽  
Lower Urinary

Material and methods. The study included patients (n=164) in peri- and postmenopause, having a laboratory-confirmed picture of the genitourinary menopausal syndrome - atrophic vulvovaginitis and suffering from recurrent lower urinary tract infections (UTI) - cystitis and urethritis. All patients underwent standard antibacterial therapy (ABT) UTI in accordance with the results of bacteriological urine culture according to Russian clinical guidelines on urology. Against the background of ABT, 164 patients received additional therapy with Trioginal® (the study group - SG) containing estriol, micronized progesterone and Lactobacillus casei rhamnosus Doderleini 35 (LCR 35) lactobacillus strain. Trioginal® was administered intravaginally in two stages: for 20 days, 2 capsules per day, then for 10 days, 1 capsule per day. In the comparison group - CG (n=67) with ABT, Ovipol Klio® (estriol monopreparation) was additionally intravaginally used in two stages: for 14 days, 1 suppository per day, then for 2 weeks, 1 suppository 2 times a week. The control group consisted of 30 patients receiving only standard ABT UTI, local hormone therapy for vulvovaginal atrophy (VVA) was not performed. The observation period was 12 months after the end of the course of therapy. At all stages of treatment, a subjective and objective assessment of the severity of urination disorders and urogenital atrophy (UDI-6 questionnaire), their impact on the quality of life of patients (questionnaire IIQ-7), indicators of bacteriuria, bacterial urine culture and vaginal biocenosis, frequency of undesirable phenomena were carried out. According to the initial characteristics of the group of patients were comparable. Results. At all stages of the study, in the group of patients who received therapy with the use of the Trioginal® drug, there was a significant improvement in the clinical picture of urination disorders compared to the CG and the control (main) group - MG (in SG - 18% at the end of therapy versus 100% before the start of therapy; CG - 26 % versus 100% respectively; Ledger - 58% versus 100% respectively; p

Pomegranate Extract Improves Menopausal Syndrome in Ovariectomized Rats

2015 ◽  
Vol 44 (4) ◽  
pp. 506-515
Author(s):  
Ji-Hyang Wee ◽  
Hyun Jung Jung ◽  
Kyung Ok Jung ◽  
Hea Mi Sung ◽  
Yu-Rim Shin ◽  
...  
Keyword(s):  
Ovariectomized Rats ◽  
Menopausal Syndrome

scholarly journals Pharmacological properties of durva swaras (Cynodon dactylon L. Pers.) in an ovariectomised rat model mimicking chronic menopausal syndrome

2021 ◽  
Vol 142 ◽  
pp. 111976
Author(s):  
Vandana Singh ◽  
Anita Singh ◽  
Syed Shah Yousuf Hussain Quadri ◽  
MV Surekha ◽  
Jerald Mahesh ◽  
...  
Keyword(s):  
Rat Model ◽  
Cynodon Dactylon ◽  
Pharmacological Properties ◽  
Menopausal Syndrome

scholarly journals Identification of the Active Ingredient and Beneficial Effects of Vitex rotundifolia Fruits on Menopausal Symptoms in Ovariectomized Rats

Biomolecules ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1033
Author(s):  
Ji Hwan Lee ◽  
Sullim Lee ◽  
Quynh Nhu Nguyen ◽  
Hung Manh Phung ◽  
Myoung-Sook Shin ◽  
...  
Keyword(s):  
Weight Gain ◽  
Body Weight Gain ◽  
Animal Experiments ◽  
Ovariectomized Rats ◽  
Biological Functions ◽  
Menopausal Syndrome ◽  
Active Constituents ◽  
Mcf 7

Estrogen replacement therapy is a treatment to relieve the symptoms of menopause. Many studies suggest that natural bioactive ingredients from plants resemble estrogen in structure and biological functions and can relieve symptoms of menopause. The fruit of V. rotundifolia, called “Man HyungJa” in Korean, is a traditional medicine used to treat headache, migraine, eye pain, neuralgia, and premenstrual syndrome in Korea and China. The aim of the present study was to confirm that V. rotundifolia fruit extract (VFE) exerts biological functions similar to those of estrogen in menopausal syndrome. We investigated its in vitro effects on MCF-7 cells and in vivo estrogen-like effects on weight gain and uterine contraction in ovariectomized rats. Using the polar extract, the active constituents of VFE (artemetin, vitexicarpin, hesperidin, luteolin, vitexin, and vanillic acid) with estrogen-like activity were identified in MCF-7 cells. In animal experiments, the efficacy of VFE in ameliorating body weight gain was similar to that of estrogen, as evidenced from improvements in uterine atrophy. Vitexin and vitexicarpin are suggested as the active constituents of V. rotundifolia fruits.

scholarly journals Utilization of Isoflavones in Soybeans for Women with Menopausal Syndrome: An Overview

2021 ◽  
Vol 22 (6) ◽  
pp. 3212 ◽  
Author(s):  
Li-Ru Chen ◽  
Kuo-Hu Chen
Keyword(s):  
Hormone Replacement ◽  
Cancer Recurrence ◽  
Therapeutic Effects ◽  
Soy Lecithin ◽  
Menopausal Syndrome ◽  
Inorganic Constituents ◽  
Study Designs ◽  
Urogenital Symptoms ◽  
Preventive Effects

Based on their nutrient composition, soybeans and related foods have been considered to be nutritious and healthy for humans. Particularly, the biological activity and subsequent benefits of soy products may be associated with the presence of isoflavone in soybeans. As an alternative treatment for menopause-related symptoms, isoflavone has gained much popularity for postmenopausal women who have concerns related to undergoing hormone replacement therapy. However, current research has still not reached a consensus on the effects of isoflavone on humans. This overview is a summary of the current literature about the processing of soybeans and isoflavone types (daidzein, genistein, and S-equol) and supplements and their extraction and analysis as well as information about the utilization of isoflavones in soybeans. The processes of preparation (cleaning, drying, crushing and dehulling) and extraction of soybeans are implemented to produce refined soy oil, soy lecithin, free fatty acids, glycerol and soybean meal. The remaining components consist of inorganic constituents (minerals) and the minor components of biologically interesting small molecules. Regarding the preventive effects on diseases or cancers, a higher intake of isoflavones is associated with a moderately lower risk of developing coronary heart disease. It may also reduce the risks of breast and colorectal cancer as well as the incidence of breast cancer recurrence. Consumption of isoflavones or soy foods is associated with reduced risks of endometrial and bladder cancer. Regarding the therapeutic effects on menopausal syndrome or other diseases, isoflavones have been found to alleviate vasomotor syndromes even after considering placebo effects, reduce bone loss in the spine and ameliorate hypertension and in vitro glycemic control. They may also alleviate depressive symptoms during pregnancy. On the other hand, isoflavones have not shown definitive effects regarding improving cognition and urogenital symptoms. Because of lacking standardization in the study designs, such as the ingredients and doses of isoflavones and the durations and outcomes of trials, it currently remains difficult to draw overall conclusions for all aspects of isoflavones. These limitations warrant further investigations of isoflavone use for women’s health.

Sign in / Sign up

Export Citation Format

Share Document